These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 24307952)

  • 1. Angiotensin-Converting Enzyme Inhibitors (ACEIs) and Angiotensin-Receptor Blockers (ARBs) in Patients at High Risk of Cardiovascular Events: A Meta-Analysis of 10 Randomised Placebo-Controlled Trials.
    Ong HT; Ong LM; Ho JJ
    ISRN Cardiol; 2013 Nov; 2013():478597. PubMed ID: 24307952
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of Angiotensin-Converting Enzyme Inhibitors and Angiotensin-Receptor Blockers in Coronary Artery Disease without Heart Failure in the Modern Statin Era: a Meta-Analysis of Randomized-Controlled Trials.
    Hoang V; Alam M; Addison D; Macedo F; Virani S; Birnbaum Y
    Cardiovasc Drugs Ther; 2016 Apr; 30(2):189-98. PubMed ID: 26861251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis.
    Cheng J; Zhang W; Zhang X; Han F; Li X; He X; Li Q; Chen J
    JAMA Intern Med; 2014 May; 174(5):773-85. PubMed ID: 24687000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers in Patients Without Heart Failure? Insights From 254,301 Patients From Randomized Trials.
    Bangalore S; Fakheri R; Toklu B; Ogedegbe G; Weintraub H; Messerli FH
    Mayo Clin Proc; 2016 Jan; 91(1):51-60. PubMed ID: 26763511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ACE Inhibitor Benefit to Kidney and Cardiovascular Outcomes for Patients with Non-Dialysis Chronic Kidney Disease Stages 3-5: A Network Meta-Analysis of Randomised Clinical Trials.
    Zhang Y; He D; Zhang W; Xing Y; Guo Y; Wang F; Jia J; Yan T; Liu Y; Lin S
    Drugs; 2020 Jun; 80(8):797-811. PubMed ID: 32333236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative Effectiveness of Combination Therapy with Statins and Angiotensin-Converting Enzyme Inhibitors versus Angiotensin II Receptor Blockers in Patients with Coronary Heart Disease: A Nationwide Population-Based Cohort Study in Korea.
    Lee J; Lee S
    Pharmacotherapy; 2018 Nov; 38(11):1095-1105. PubMed ID: 30225928
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and combined therapy in patients with micro- and macroalbuminuria and other cardiovascular risk factors: a systematic review of randomized controlled trials.
    Maione A; Navaneethan SD; Graziano G; Mitchell R; Johnson D; Mann JF; Gao P; Craig JC; Tognoni G; Perkovic V; Nicolucci A; De Cosmo S; Sasso A; Lamacchia O; Cignarelli M; Manfreda VM; Gentile G; Strippoli GF
    Nephrol Dial Transplant; 2011 Sep; 26(9):2827-47. PubMed ID: 21372254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on cardiovascular events in patients with heart failure: a meta-analysis of randomized controlled trials.
    Tai C; Gan T; Zou L; Sun Y; Zhang Y; Chen W; Li J; Zhang J; Xu Y; Lu H; Xu D
    BMC Cardiovasc Disord; 2017 Oct; 17(1):257. PubMed ID: 28982370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on cardiovascular events and residual renal function in dialysis patients: a meta-analysis of randomised controlled trials.
    Liu Y; Ma X; Zheng J; Jia J; Yan T
    BMC Nephrol; 2017 Jun; 18(1):206. PubMed ID: 28666408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular outcomes in high-risk patients without heart failure treated with ARBs: a systematic review and meta-analysis.
    Al Khalaf MM; Thalib L; Doi SA
    Am J Cardiovasc Drugs; 2009; 9(1):29-43. PubMed ID: 19178130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and tolerability of angiotensin-converting enzyme inhibitor versus the combination of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker in patients with left ventricular dysfunction: a systematic review and meta-analysis of randomized controlled trials.
    Lakhdar R; Al-Mallah MH; Lanfear DE
    J Card Fail; 2008 Apr; 14(3):181-8. PubMed ID: 18381180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of renin-angiotensin system blockers on renal and cardiovascular outcomes in patients with diabetic nephropathy: a meta-analysis of randomized controlled trials.
    Liu X; Ma L; Li Z
    J Endocrinol Invest; 2020 Jul; 43(7):959-972. PubMed ID: 31939197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiotensin receptor blockers for heart failure.
    Heran BS; Musini VM; Bassett K; Taylor RS; Wright JM
    Cochrane Database Syst Rev; 2012 Apr; 2012(4):CD003040. PubMed ID: 22513909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Angiotensin II Receptor Blockers and Cancer Risk: A Meta-Analysis of Randomized Controlled Trials.
    Zhao YT; Li PY; Zhang JQ; Wang L; Yi Z
    Medicine (Baltimore); 2016 May; 95(18):e3600. PubMed ID: 27149494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on cardiovascular outcomes in hypertensive patients with type 2 diabetes mellitus: A PRISMA-compliant systematic review and meta-analysis.
    Lv X; Zhang Y; Niu Y; Song Q; Zhao Q
    Medicine (Baltimore); 2018 Apr; 97(15):e0256. PubMed ID: 29642146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular effects of angiotensin converting enzyme inhibition or angiotensin receptor blockade in hemodialysis: a meta-analysis.
    Tai DJ; Lim TW; James MT; Manns BJ; Tonelli M; Hemmelgarn BR;
    Clin J Am Soc Nephrol; 2010 Apr; 5(4):623-30. PubMed ID: 20133488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials.
    Bangalore S; Kumar S; Kjeldsen SE; Makani H; Grossman E; Wetterslev J; Gupta AK; Sever PS; Gluud C; Messerli FH
    Lancet Oncol; 2011 Jan; 12(1):65-82. PubMed ID: 21123111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiotensin-converting enzyme inhibitors (ACEIs), not angiotensin receptor blockers (ARBs), are preferred and effective mode of therapy in high cardiovascular risk patients.
    Vijan SG
    J Indian Med Assoc; 2009 Mar; 107(3):178-82. PubMed ID: 19810392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of Outcomes Between Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Patients With Myocardial Infarction: A Meta-Analysis.
    Escobar J; Rawat A; Maradiaga F; Isaak AK; Zainab S; Arusi Dari M; Mekonen Gdey M; Khan A
    Cureus; 2023 Oct; 15(10):e47954. PubMed ID: 38034144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distinct survival benefits of angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers in revascularized coronary artery disease patients according to history of myocardial infarction.
    Nishino T; Furukawa Y; Kaji S; Ehara N; Shiomi H; Kim K; Kitai T; Kinoshita M; Morimoto T; Sakata R; Kimura T;
    Circ J; 2013; 77(5):1242-52. PubMed ID: 23291989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.